Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and preliminary efficacy of NovoSeven in brain contusions
2004-000088-92Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing NovoSeven with Placebo (2 arms). Primary endpoint: Serious adverse events within 15 days. Started Jun 2004; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on 2004-000088-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000088-92.